New Risk • May 21
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (₩95.3b market cap, or US$63.3m). Ankündigung • Feb 28
Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026 Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩800 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%). Reported Earnings • Nov 19
Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024) Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Declared Dividend • Nov 08
Dividend of ₩800 announced Dividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 28th April 2026 Dividend yield will be 4.8%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (34% cash payout ratio). The dividend has increased by an average of 18% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Nov 07
Sam-A Pharm. Co., Ltd announces Annual dividend, payable on April 28, 2026 Sam-A Pharm. Co., Ltd announced Annual dividend of KRW 800.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Reported Earnings • May 20
First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024) First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Ankündigung • Mar 01
Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025 Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩750 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%). New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩130.9b market cap, or US$99.5m). New Risk • Sep 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.1b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩132.1b market cap, or US$99.0m). Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩25,350, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 69% over the past three years. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₩27,200, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years. Buy Or Sell Opportunity • Jul 01
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 35% to ₩22,000. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩22,500, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 47% over the past three years. Buy Or Sell Opportunity • Jun 20
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 36% to ₩22,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩123.9b market cap, or US$89.7m). Buy Or Sell Opportunity • May 29
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 26% to ₩21,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • May 18
First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023) First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 32% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩400 per share at 2.4% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 12 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%). Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022) Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • May 19
First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022) First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 21
Upcoming dividend of ₩250 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 14 April 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 17% share price gain to ₩18,550, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 22% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩300 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 02 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Is New 90 Day High Low • Mar 10
New 90-day low: ₩14,500 The company is down 16% from its price of ₩17,350 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period. Is New 90 Day High Low • Jan 15
New 90-day low: ₩15,600 The company is down 10.0% from its price of ₩17,350 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period. Reported Earnings • Dec 03
Third quarter 2020 earnings released: ₩111 loss per share The company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: ₩12.2b (down 26% from 3Q 2019). Net loss: ₩675.4m (down 135% from profit in 3Q 2019). Is New 90 Day High Low • Oct 22
New 90-day low: ₩16,300 The company is down 16% from its price of ₩19,500 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.